ESPERION THERAPEUTICS INC (ESPR) Stock Price, Quote, News and Overview
NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock - Currency: USD
ESPR Quote, Performance and Key Statistics
ESPERION THERAPEUTICS INC
NASDAQ:ESPR (1/24/2025, 4:49:03 PM)
After market: 2.1 0 (0%)2.1
+0.02 (+0.96%)
The current stock price of ESPR is 2.1 USD. In the past month the price decreased by -6.25%. In the past year, price decreased by -1.41%.
ESPR Latest News, Press Releases and Analysis
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09,...
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd...
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million...
ESPR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 77.23 | 745.61B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.62 | 390.70B | ||
| JNJ | JOHNSON & JOHNSON | 14.7 | 353.49B | ||
| MRK | MERCK & CO. INC. | 16.06 | 241.71B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.13 | 214.16B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.4 | 199.87B | ||
| PFE | PFIZER INC | 10.11 | 147.85B | ||
| SNY | SANOFI-ADR | 12.56 | 131.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51 | 121.02B | ||
| ZTS | ZOETIS INC | 29.27 | 76.07B | ||
| GSK | GSK PLC-SPON ADR | 8.34 | 69.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.65 | 41.18B |
Related stock screener links
About ESPR
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 240 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The firm's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
Company Info
ESPERION THERAPEUTICS INC
3891 Ranchero Drive, Suite 150, Suite 300
Ann Arbor MICHIGAN 48108 US
CEO: Tim M. Mayleben
Employees: 240
Company Website: https://www.esperion.com/
Investor Relations: https://www.esperion.com/investors-media
Phone: 17348873903
ESPR FAQ
What is the stock price of ESPR?
The current stock price of ESPR is 2.1 USD.
What is the symbol for ESPERION THERAPEUTICS INC stock?
The exchange symbol of ESPERION THERAPEUTICS INC is ESPR and it is listed on the Nasdaq exchange.
On which exchange is ESPR stock listed?
ESPR stock is listed on the Nasdaq exchange.
Is ESPR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ESPR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ESPR.
Does ESPR stock pay dividends?
ESPR does not pay a dividend.
What is the Price/Earnings (PE) ratio of ESPR?
ESPR does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
What is the Short Interest ratio of ESPR stock?
The outstanding short interest for ESPR is 16.5% of its float.
ESPR Technical Analysis
ESPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ESPR. ESPR has a bad profitability rating. Also its financial health evaluation is rather negative.
ESPR Financial Highlights
Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by 73.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to ESPR. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 85.61% and a revenue growth 190.11% for ESPR